Lilly teams up with PRISM BioLab on protein interaction targets

2023-11-28

引进/卖出蛋白降解靶向嵌合体

Eli Lilly has reached an agreement to use PRISM BioLab's platform to discover oral inhibitors of protein-protein interaction (PPI) targets. "Our PepMetics technology holds promise to change the current paradigm in drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules," remarked Dai Takehara, CEO at PRISM, in a company statement Tuesday.

PepMetics are a class of small molecules that mimic 3D structures of alpha-helix and beta-turn, which are peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. According to PRISM, the technology can render previously undruggable PPIs into targets readily druggable with small molecules, while also creating oral alternatives for injectable biologics.

Up to $660 million in milestones

Under the deal, the companies will work together using the PepMetics platform to discover small molecule inhibitors of a PPI target chosen by Eli Lilly. PRISM will receive unspecified upfront payments and is eligible for up to $660 million in preclinical, clinical and commercial development milestones, as well as sales royalties. Eli Lilly may also add up to two more targets to the collaboration and is responsible for clinically developing and commercialising any resulting products.

PepMetics targeting CREB-binding protein/beta-catenin PPIs, licensed to Eisai and Ohara Pharmaceuticals, are in clinical development for cancer and liver disease, respectively. PRISM has also previously struck drug discovery collaborations with Roche and Servier.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构